22:32 , May 14, 2018 |  BC Extra  |  Company News

Management tracks: Complexa, Immatics

Fibrotic and inflammatory disease company Complexa Inc. (Berwyn, Pa.) hired Francisco Salva as president and CEO. He was co-founder and VP of operations at Acerta Pharma B.V. (Oss, Netherlands). Immunotherapy company Immatics Biotechnologies GmbH (Tuebingen, Germany)...
22:28 , May 7, 2018 |  BC Extra  |  Company News

Management tracks: Adverum, Evolus

Adverum Biotechnologies Inc. (NASDAQ:ADVM) said President and CEO Amber Salzman has stepped down. CFO and SVP Leone Patterson is acting as interim president and CEO while the gene therapy company searches for a successor. Additionally,...
03:28 , Jan 19, 2018 |  BC Innovations  |  Tools & Techniques

Synthetic expressions

Bringing synthetic biology to transcriptional regulation could catalyze a new generation of gene therapies that are more tunable, disease-specific and easy to deliver than the products dominating the field. The new constructs include synthetic promoters that...
22:52 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

Adverum begins Phase I/II of ADVM-043 for AAT deficiency

Adverum Biotechnologies Inc. (NASDAQ:ADVM) began the Phase I/II ADVANCE trial to evaluate ADVM-043 in up to 20 patients with alpha-1 antitrypsin (AAT; A1AT; SERPINA1) deficiency. The study will enroll up to four cohorts, with the first...
00:25 , Jun 21, 2017 |  BC Extra  |  Company News

Management tracks

Biogen Inc. (NASDAQ:BIIB) named Ginger Gregory EVP and chief human resources officer, effective July 17. She was chief human resources officer at Shire plc (LSE:SHP; NASDAQ:SHPG). Neurodegenerative, inflammation and cancer company Active Biotech AB (SSE:ACTI) promoted...
00:35 , Jan 21, 2017 |  BC Extra  |  Company News

Management tracks

Gene therapy company Genenta Science s.r.l. (Milan, Italy) named Carlo Russo CMO. Russo was CMO at Adverum Biotechnologies Inc. (NASDAQ:ADVM). Sosei Group Corp. (Tokyo:4565) named Andrew Oakley CFO, effective Feb. 1. He replaces Hidetoshi Torami,...
07:00 , Oct 14, 2016 |  BC Extra  |  Company News

Management tracks

Gene therapy company Adverum Biotechnologies Inc. (NASDAQ:ADVM) named Amber Salzman CEO, replacing Paul Cleveland. Salzman was president and COO, and will remain president. Cleveland will be the company's executive chairman. Cell therapy company Kite Pharma...
07:00 , Sep 22, 2016 |  BC Innovations  |  Strategy

In the CRISPR tea leaves

The four foundational CRISPR companies have stayed tight-lipped about their plans and progress, providing few details about their development strategies or intended indications. But as they have ramped up partnering in the last few months...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Company News

Adverum, Editas Medicine deal

Editas and Adverum partnered to develop gene editing-based treatments for up to five inherited retinal diseases. The deal combines Adverum’s next-generation adeno-associated viral (AAV) vectors with Editas’ CRISPR-based genome editing technologies. Editas will pay Adverum...
07:00 , Aug 9, 2016 |  BC Extra  |  Company News

Editas, Adverum partner to treat retinal diseases

Editas Medicine Inc. (NASDAQ:EDIT) and Adverum Biotechnologies Inc. (NASDAQ:ADVM) will collaborate to develop gene editing-based treatments for up to five inherited retinal diseases. The deal combines Adverum's next-generation adeno-associated viral (AAV) vectors with Editas' genome...